GNE

Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase · Q9Y223 · GNE on Sugi Atlas →

863 patent compounds predicted against GNE, 648 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL12168473	0.97	1/20
SCHEMBL20854826	0.93	1/20
SCHEMBL5237	0.68	1/20
SCHEMBL3249427	0.68	1/20
SCHEMBL29024492	0.67	1/20
SCHEMBL29024494	0.67	1/20
SCHEMBL2532948	0.66	1/20
SCHEMBL3244751	0.66	1/20
SCHEMBL18254471	0.63	1/20
SCHEMBL18245950	0.62	1/20
SCHEMBL18254257	0.62	1/20
SCHEMBL7245767	0.62	1/20
Dipicolinic Acid (SCHEMBL34595)	0.61	1/20
Dipicolinic Acid (SCHEMBL720696)	0.61	1/20
SCHEMBL27422387	0.60	1/20
SCHEMBL836939	0.60	1/20
Hydrochloric Acid (SCHEMBL7252859)	0.60	1/20
Dipicolinic Acid (SCHEMBL321128)	0.59	1/20
Dipicolinic Acid (SCHEMBL890374)	0.59	1/20
Dipicolinic Acid (SCHEMBL890375)	0.59	1/20

Clinical trials — most relevant to GNE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)	PHASE3	COMPLETED
Efficacy Confirmation Study of NPC-09	PHASE3	COMPLETED
NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions	PHASE3	RECRUITING
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy	PHASE2	COMPLETED
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG	PHASE2	COMPLETED
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients	PHASE2	ENROLLING_BY_INVITATION
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses	PHASE2	COMPLETED
Oral N-acetylglucosamine in Crohn's Disease	PHASE2	NOT_YET_RECRUITING
Efficacy of Sialic Acid GNE Related Thrombocytopenia	PHASE2	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
A Study of GlcNAc on Tear Production in NGLY1-CDDG	PHASE2	ACTIVE_NOT_RECRUITING
Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)	PHASE1	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers	PHASE1	COMPLETED
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Clinical, Biological and NMR Outcome Measures Study for Hereditary Inclusion Body Myopathy Due to Mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine Kinase Gene (GNE)	nan	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children	nan	RECRUITING
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Intervention and Outcomes in Duarte Galactosemia	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Registry Gangliosidoses	nan	UNKNOWN
The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia	nan	COMPLETED
Dietary Monosaccharide Supplementation in Patients With Congenital Disorders of Glycosylation	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GNE binder may also engage these)

Protein	Name	Similarity
O35826	—	1.000	O35826 →
Q7TQ49	—	1.000	Q7TQ49 →
Q91WG8	—	1.000	Q91WG8 →
O02373	—	0.987	O02373 →
A4Y447	—	0.984	A4Y447 →
Q64VX4	—	0.983	Q64VX4 →
Q9WVS2	—	0.982	Q9WVS2 →
Q8CNK9	—	0.982	Q8CNK9 →
Q5HMF5	—	0.982	Q5HMF5 →
E6SRG2	—	0.981	E6SRG2 →
Q2GXN6	—	0.981	Q2GXN6 →
B7MMH6	—	0.981	B7MMH6 →
Q92210	—	0.981	Q92210 →
A6WK72	—	0.981	A6WK72 →
A3D1A0	—	0.981	A3D1A0 →
Q0HS20	—	0.981	Q0HS20 →
Q5RHZ6	—	0.981	Q5RHZ6 →
A7SXZ6	—	0.980	A7SXZ6 →
P26404	—	0.980	P26404 →
A8NEP3	—	0.980	A8NEP3 →
O85342	—	0.980	O85342 →
E1WTS4	—	0.980	E1WTS4 →
Q19905	—	0.980	Q19905 →
A0L052	—	0.980	A0L052 →
B7LM76	—	0.980	B7LM76 →
Q5LEY1	—	0.980	Q5LEY1 →
A1CM94	—	0.980	A1CM94 →
P41564	—	0.980	P41564 →
Q5ZUS0	—	0.980	Q5ZUS0 →
Q0TVK3	—	0.980	Q0TVK3 →